MEDLIVE (02192) · Company profile · Eqvero

MEDLIVE

02192HKEX

Unit: CNY	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	642.16 m CNY	558.46 m CNY	412 m CNY	314.05 m CNY	284.44 m CNY
Cost of revenue	235.63 m CNY	215.63 m CNY	151.3 m CNY	92.33 m CNY	77.56 m CNY
Research and development expense	76.53 m CNY	64.58 m CNY	54.26 m CNY	46.23 m CNY	25.33 m CNY
Selling, general and administrative expense	217.04 m CNY	208.99 m CNY	177.13 m CNY	150.96 m CNY	127.4 m CNY
Operating profit after depreciation	167.36 m CNY	117.44 m CNY	65.14 m CNY	60.2 m CNY	61.87 m CNY
Operating profit before depreciation	188.45 m CNY	133.04 m CNY	74.51 m CNY	69.19 m CNY	68.02 m CNY
EBIT	167.36 m CNY	117.44 m CNY	65.14 m CNY	60.2 m CNY	61.87 m CNY
EBITDA	188.45 m CNY	133.04 m CNY	74.51 m CNY	69.19 m CNY	68.02 m CNY
Interest expense	552 k CNY	786 k CNY	361 k CNY	531 k CNY	535 k CNY
Profit before tax	360.29 m CNY	340.47 m CNY	253.13 m CNY	135.04 m CNY	69.93 m CNY
Income tax expense	12.4 m CNY	10.17 m CNY	1.37 m CNY	8.62 m CNY	24.68 m CNY
Income before extraordinary items	334.34 m CNY	315.15 m CNY	242.3 m CNY	117.32 m CNY	40.62 m CNY
Common dividends	191.49 m CNY	188.42 m CNY	168.74 m CNY	46.93 m CNY	12.13 m CNY
Total dividends	191.49 m CNY	188.42 m CNY	168.74 m CNY	46.93 m CNY	12.13 m CNY

Quotes are end-of-day data. Content is for research purposes and is not investment advice.